EUCTR2017-002781-48-DE进行中（未招募）1 期
International, multicenter, randomized, open-label, phase II clinical trial to evaluate the efficacy and safety of continuation of palbociclib in combination with second-line endocrine therapy in HormoneReceptor-positive/HER2-negative advanced breast cancer patients who have achieved clinical benefit during first-line palbociclib-based treatment - Palbociclib rechallenge in hormone receptor-posItive/HER2-negative advanced breast cancer (PALMIRA)
Medica Scientia Innovation Research (MedSIR)0 个研究点目标入组 198 人开始时间: 2019年2月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 198
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1.- Female patients #18 years of age. 2.- Pre-menopausal (treated with a LHRH analogue for at least 28 days) or post-menopausal women. 3.- ECOG 0 - 1. 4.- Life expectancy #12 weeks. 5.- ABC not amenable to curative treatment. 6.- HR-positive and/or HER2-negative. 7.- Disease progression on first-line combination of palbociclib + endocrine therapy (AI or fulvestrant). 8.- Clinical benefit to a first-line palbociclib-based endocrine regimen. 9.- Previous palbociclib dose: min 75mg during the last 2 cycles. 10.- Last dose of palbociclib administered not later than 8 weeks and not earlier than 7 days from study entry, (except in the adjuvant setting).
- •11.- Patients should not have been treated in the advanced setting with at least one of these endocrine therapy options: either fulvestrant or AI. Note: Patients treated with adjuvant AI with a disease- free interval # 12 months, and with first-line fulvestrant in the metastatic setting, could receive treatment with an AI in themetastatic setting. 12.- Measurable or evaluable disease acc. RECIST v.1.1.
- •Patients with only bone lesions are eligible. 13.- Tumor tissue biopsy (if feasible) from a metastatic site or the primary breast tumor, both at inclusion and after disease progression for exploratory studies. If not feasible, eligibility to be evaluated by Sponsor’s designee. 14.- Patients agree to collection of blood samples (liquid biopsy) at inclusion, after 2 weeks of treatment, and upon progression or study termination. 15.- Adequate organ function. 16.- Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. 17.- Patients informed and signed informed consent. 18.- Resolution of all acute toxic effects of prior anti- cancer therapy to grade
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 148
排除标准
- •1. HR or HER2 unknown disease. 2. HER2-positive disease based on local laboratory results (performed by IHC / ISH test). 3. Locally ABC candidate for curative treatment.4. Formal contraindication to endocrine therapy defined as visceral crisis and rapidly or symptomatic progressive visceral disease. 5. Prior therapy with any other CDK4/6 inhibitor different from palbociclib. 6. Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases, carcinomatous meningitis, or leptomeningeal disease as indicated by clinical symptoms, cerebral edema, and/or progressive growth. Patients with a history of CNS metastases or cord compression are eligible if they have been definitively treated (e.g., radiotherapy, stereotactic surgery) and are clinically stable off anticonvulsants and steroids for at least 4 weeks before randomization. 7. Patients are currently receiving food or drugs known to be strong inducers or inhibitors of CYP3A4 (see Section 3.5 for details on prohibited medications). 8. Current or prior malignancy which could affect compliance with the protocol or interpretation of results. Patients with curatively- treated non-melanoma skin cancer, non-muscle-invasive bladder cancer, or carcinoma in situ, among others, are generally eligible. 9. No other systemic therapy for metastatic disease including chemotherapy, immunotherapy, targeted therapy (small molecules/ monoclonal antibodies), or endocrine therapy excluding first-line palbociclib-based regimen. 10. Major surgery (defined as requiring general anesthesia) or significant traumatic injury within 2 weeks of start of study drug, or patients who have not recovered from the side effects of any major surgery, or patients who may require major surgery during the study. 11. Radiotherapy or limited-field palliative radiotherapy within 7 days prior to study enrolment, or patients who have not recovered from radiotherapy-related toxicities to baseline or grade # 1 and/or from whom # 25% of the bone marrow has been previously irradiated. 12. Use of concurrent investigational agents or other concomitant anticancer therapies. 13. Active bleeding diathesis, previous history of bleeding diathesis, or chronic anti-coagulation treatment (the use of low molecular weight heparin is allowed as soon as it is used as prophylaxis intention). 14. Serious concomitant systemic disorder (e.g., active infection including HIV, or cardiac disease) incompatible with the study (at the discretion of investigator). 15. Unable to swallow capsules or tablets. 16. History of malabsorption syndrome or other condition that would interfere with enteral absorption. 17. Any of the following within 6 months of randomization: myocardial infarction, severe/unstable angina, ongoing cardiac dysrhythmias of NCI-CTCAE v.5.0 grade #2, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident including transient ischemic attack, or symptomatic pulmonary embolism. 18. Uncontrolled electrolyte disorders of NCI-CTCAE v.5.0 grade #2. 19. Known hypersensitivity to palbociclib or any of its excipients.
研究者
相似试验
进行中（未招募）
不适用
A observational study of efficacy and safety of medicinal drugs Dalteparin Sodium, solution for intravenous and subcutaneous administratioCTRI/2016/10/007400JSC Pharmasyntez190
进行中（未招募）
不适用
International, multicenter, randomised, open-labeled, 2-arm - Phase III Study comparing Imatinib (STI571, Glivec®) Standard Dose (400 mg/day) with Imatinib High Dose Induction (800 mg/day) followed by Imatinib Standard Dose Maintenance (400 mg/day) in pretreated Ph+/BCR-ABL+ CML Patients in Chronic Phase - ISTAHITpatients with chronic myelogenous leukemia in chronic phase (Ph+/BCR-ABL+)EUCTR2004-000881-10-LTCELSG (Central European Leukemia Study Group)240
尚未招募
不适用
Efficacy and Safety of the Drug Product CaspofungiCTRI/2017/04/008362JSC Pharmasyntez Russia244
已完成
不适用
To compare effectiveness and drug safety of Flusal, aerosol for inhalation metered dose and Seretide®, inhalation aerosol metered dose in patients with uncontrolled and partially controlled bronchial asthmaCTRI/2015/11/006380OOO Rus Biopharm120
进行中（未招募）
1 期
_EUCTR2014-002560-33-FRICANCER180